Pasithea Therapeutics (KTTA) Share-based Compensation (2021 - 2026)
Pasithea Therapeutics recorded quarterly Share-based Compensation of $136000.0 in Q1 2026, up 54.06% quarter-over-quarter from $88277.0 in Q4 2025, and up 2620.0% year-over-year from $5000.0 in Q1 2025.
Pasithea Therapeutics' Share-based Compensation history runs 6 years deep, the most recent figure standing at $136000.0 for Q1 2026.
- In Q1 2026, Share-based Compensation rose 2620.0% year-over-year to $136000.0; the TTM figure through Mar 2026 stood at $332277.0 (up 17.67% YoY), while the FY2025 annual figure was $297467.0, down 61.55% from the prior year.
- Share-based Compensation came in at $136000.0 for Q1 2026 at Pasithea Therapeutics, up from $88277.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $195000.0 in Q2 2023 to a low of $5000.0 in Q1 2025.
- A 5-year average of $101966.2 and a median of $102000.0 in 2023 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation sank 93.06% in 2025 and surged 2620.0% in 2026, its largest moves.
- Pasithea Therapeutics' Share-based Compensation stood at $156174.0 in 2022, then tumbled by 55.22% to $69940.0 in 2023, then soared by 69.26% to $118383.0 in 2024, then declined by 25.43% to $88277.0 in 2025, then soared by 54.06% to $136000.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $136000.0, $88277.0, and $52000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - | 136,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 136,000.00 |
| Mar 31, 2026 | 136,000.00 |
| Dec 31, 2025 | 88,277.00 |
| Dec 31, 2025 | 88,277.00 |
| Jun 30, 2025 | 58,000.00 |
| Jun 30, 2025 | 58,000.00 |
| Dec 31, 2024 | 118,383.00 |
| Dec 31, 2024 | 118,383.00 |
| Sep 30, 2024 | 2,360.00 |
| Sep 30, 2024 | 2,360.00 |
| Jun 30, 2024 | 2,360.00 |
| Jun 30, 2024 | 2,360.00 |
| Mar 31, 2024 | 72,000.00 |
| Mar 31, 2024 | 72,000.00 |
| Dec 31, 2023 | 69,940.00 |
| Dec 31, 2023 | 69,940.00 |
| Sep 30, 2023 | 102,000.00 |
| Sep 30, 2023 | 102,000.00 |
| Jun 30, 2023 | 195,000.00 |
| Jun 30, 2023 | 195,000.00 |
| Mar 31, 2023 | 177,021.00 |
| Mar 31, 2023 | 177,021.00 |
| Dec 31, 2022 | 156,174.00 |
| Dec 31, 2022 | 156,174.00 |
| Sep 30, 2022 | 111,000.00 |
| Sep 30, 2022 | 111,000.00 |
| Jun 30, 2022 | 100,000.00 |
| Jun 30, 2022 | 100,000.00 |
| Mar 31, 2022 | 135,630.00 |
| Mar 31, 2022 | 135,630.00 |
| Dec 31, 2021 | 720,000.00 |
| Dec 31, 2021 | 720,000.00 |
| Sep 30, 2021 | -270,000.00 |
| Sep 30, 2021 | -270,000.00 |
| Jun 30, 2021 | 300,000.00 |
| Jun 30, 2021 | 300,000.00 |